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STEAP was identiﬁed by the strategy of suppression subtractive hybridizations in Los Ange-
les prostate cancer xenografts. It is expressed in prostate and other cancers, and not in most
normal tissue; it can be used as a marker to evaluate biological samples from individuals
suspected of having a disease associated with STEAP dysregulation, such as cancers, and
may provide prognostic information useful in deﬁning appropriate therapeutic options.
The aim of this study was to test the STEAP mRNA detection in the serum of patients with
different malignant tumours by using Real-Time reverse transcription PCR. The results
were compared with biological samples obtained by age-matched non-malignant donors.
Our data demonstrated that STEAP mRNA is detectable in serum of patients with differ-
ent solid tumours whereas it is not ampliﬁable in non-malignant donors.
This marker revealed with the molecular method of quantitative PCR in serum, may be
useful to discriminate normal and cancer patients.
 2008 Elsevier Ireland Ltd. All rights reserved.1. Introduction
STEAP (six-transmembrane epithelial antigen of the
prostate) was identiﬁed by the strategy of suppression
subtractive hybridizations in LAPC (Los Angeles prostate
cancer) xenografts [1]. The prototype member of the STEAP
family, STEAP-1, appears to be a membrane protein ex-
pressed predominantly in prostate cells. Structurally,
STEAP-1 is a 339 aminoacid protein characterized by a
molecular topology of six transmembrane domains and
intracellular N- and C-termini, suggesting it folds in a ‘‘ser-
pentine” manner into three extracellular and two intracel-
lular manner; this putative secondary structure may
predict that it functions as a potential channel or trans-
porter protein. STEAP is highly expressed at all steps of
prostate cancer and does not seem to be modulated by hor-
mones; it also expressed in multiple cancer while showing
restricted expression in normal human tissue [1]. In fact,
this protein over-expressed in prostatic cancer, is also
present in numerous human cancer cell line from pancreas,
colon, breast, testicular, cervical, bladder and ovarian carci-and Ltd. All rights reserved.
ax +39 045 583041.
Dalle Carbonare).noma, acute lymphocytic leukaemia and Ewing sarcoma
[2]. Since the STEAP gene family is predominantly ex-
pressed in epithelial tissues, it seems possible that the
STEAP protein function as ion channels, transports proteins
or gap-junction proteins in epithelial cell function. Ion
channels have been implicated in proliferation and inva-
siveness of prostate cancer cells [3]. Both rat and human
prostate cancer cells contain sub-population of cells with
higher and lower expression levels of sodium channels.
Higher levels of sodium channel expression correlate with
more aggressive invasiveness in vitro [4]. Similarly, it has
been shown that a speciﬁc blockade of sodium channels
inhibits the invasiveness of PC-3 cells in vitro [5], while
speciﬁc inhibition of potassium channels in LNCaP cells
inhibited cell proliferation [6]. These reports suggest a role
for ion channels in prostate cancer and also demonstrate
that small molecules that inhibit ion channel function
may interfere with prostate cancer proliferation. This large
pattern of expression strongly suggests the use of this tu-
mour antigen for diagnosis and in a broad-spectrum anti-
tumour therapy.
The ﬁnding that STEAP is expressed in prostate and other
cancers, and not in most normal tissue, provides evidence
that this gene is associated with dysregulated cell growth
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that canbeused toevaluatebiological samples fromindivid-
uals suspected of having a disease associated with STEAP
dysregulation. For example, because STEAP is so highly ex-
pressed in prostate, and not in most normal tissues, and be-
cause its expression is associated with certain cancers,
assays that evaluate the relative levels of STEAPmRNA tran-
scripts or proteins in a biological sample may be used to
diagnose a disease associated with STEAP dysregulation,
such as cancer andmayprovide prognostic informationuse-
ful in deﬁning appropriate therapeutic options.
The idea that it should be possible to obtain circulating
RNA from peripheral blood is intriguing because this is a
easily available potential biomarker representing a non-
invasive technique for diagnosing and monitoring tumours
[7]; in patients with breast, hepatocellular, colorectal and
other cancers, circulating RNA has been detected at high
levels; in addition, it has been demonstrated that circulat-
ing RNA is derived from tumour tissues [8].
STEAP mRNA detection in the serum of tumour patients
have not been investigated, probably because this marker
was recently identiﬁed. The aim of this study was to test
the STEAP mRNA detection in the serum of patients with
different malignant tumours by using Real-Time reverse
transcription PCR. Our data demonstrated that STEAP
mRNA is detectable in serum of patients with different so-
lid tumours whereas it is not ampliﬁable in non-malignant
donors; however, in the light of this ﬁnding, this marker
revealed with the molecular method of quantitative PCR
in serum, may be useful for diagnosing tumours.2. Material and methods
2.1. Patients
We selected 50 patients, consecutively hospitalized in
our Institute. Patients have previous diagnosis of solid tu-
mour or were diagnosed during the hospitalization. Pa-
tients included in the study were untreated, surgical
treated or they stopped chemotherapy at least six months
before the enrollment. Results from these patients were
compared with 29 non-malignant age-matched donors,
hospitalized in our Institution for cardiovascular or meta-
bolic diseases. All the subjects had given written informed
consent. Characteristics of the study population are
showed in Table 1.
2.2. Serum preparation
Centrifugation of collected blood and harvesting serum
samples were done by using three steps of centrifugation
(800 g with 0.45 lm ﬁltration, 1000g, and 1500g) to de-
crease lymphocyte to a minimum as previously described
[9]. The samples were then used to RNA extraction or
stored at 80 C.
2.3. RNA extraction
Total RNA was extracted from 1 ml of serum using the
QIAamp UltraSens Virus kit (Quiagen) with DNAse I treat-ment. The RNA from LNCaP culture for standard curve
was extracted from a 75-cm2 ﬂask using the RNAeasy
minikit (Quiagen) with DNAse I treatment. The amount
of extracted RNA was quantiﬁed by measuring the absor-
bance at 260 nm. The purity of the RNA was checked by
measuring the ratio of the absorbance at 260 and
280 nm, where a ratio ranging from 1.8 to 2.0 was taken
to be pure.
2.4. Reverse transcription
First-strand cDNA was generated from 1 lg of RNA
using the High-Capacity cDNA Archive Kit, with random
hexamers, (Applied Biosystems PE) according to the manu-
facturer’s protocol. RT product was aliquoted in equal vol-
umes and stored at 80 C
2.5. RT Real-Time quantiﬁcation of STEAP mRNA
PCR was performed in a total volume of 50 ll containing
1 Taqman Universal PCR Master mix, no AmpErase UNG
and 5 ll of cDNA; pre-designed, Gene-speciﬁc primers and
probe sets for each gene (STEAP; Hs00185180_m1) (Beta 2
microglobulin (B2 M); Hs99999907) were obtained from
Assay-on-Demand Gene Expression Products (Applied Bio-
systems). The real-time ampliﬁcations included 10 min at
95 C (AmpliTaq Gold activation), followed by 50 cycles
at 95 C for 15 s and at 60 C for 1 min. PCR efﬁciencies
were calculated with a relative standard curve, derived
from a four cDNA dilution series in triplicate and gave
regression coefﬁcients greater than 0.98 and efﬁciencies
greater than 90%. To normalize the STEAP mRNA expres-
sion from sample to sample in RNA input, quality and
reverse transcriptase efﬁciency, we ampliﬁed the house-
keeping gene B2M. The B2M endogenous/internal control
gene was abundant and remained constant, in proportion
to total RNA, among the samples. The STEAP and B2M ratio
represented the normalized STEAP (the STEAP/B2M ratio).
The amount of STEAP cDNA in each sample, obtained as
average of triplicates, was determined from the standard
curve and the results are expressed as pg equivalent to
STEAP RNA obtained from LNCaP and simpliﬁed as STEAP
RNA pg/ml.
2.6. Standard curves
The relative standard curves were obtained using the
STEAP and B2 M gene primers and probes in singleplex,
ampliﬁed with 10, 20, 40 and 80 pg of total RNA from
LNCaP. Each sample was run in triplicate. The curves ob-
tained for each cell line showed a linear relationship be-
tween RNA concentration and the Ct value of PCR real-
time for both STEAP gene and B2M gene.
We selected the DRn in the exponential phase of ampli-
ﬁcation plots to determine the Ct values and to obtain the
linearity of calibration curves.
2.7. Calculation of performance
Results of STEAP RT Real-Time PCR in serum were plot-
ted against disease status (present or absent) and sensitiv-
Table 1
Characteristics of the study population
Patient
No.
Age Sex Type TNM Treatment
1 64 F Pancreas T3N0M0 –
2 77 F Pancreas T4N1M1 –
3 83 F Pancreas T2N0M0 –
4 77 M Pancreas T4N1M1 –
5 77 M Pancreas T2N0M0 –
6 60 M Pancreas T2N0M0 –
7 65 F Pancreas T2N1M1 –
8 72 F Pancreas T3N2M2 –
9 68 M Pancreas T2N0M0 –
10 79 M Bladder T3N1M0 –
11 67 F Bladder T3N1M0 S
12 68 M Bladder T2N1M1 –
13 88 M Breast T2N9M1 S
14 59 F Breast T1N1M1 S + CT
15 62 F Breast T1N1M1 –
16 60 F Breast T1N1M1 –
17 61 F Breast T1N1M1 –
18 63 F Breast T1N1M1 –
19 62 F Breast T1N1M1 –
20 57 F Breast T2N1M1 –
21 76 M Prostate T3N1M1 –
22 79 M Prostate T3N1M1 CT
23 65 M Prostate T2N1M0 S
24 83 M Prostate T1N0M0 –
25 72 M Prostate T2N1M1 –
26 73 M Prostate T1N1M1 –
27 70 M Prostate T1N1M1 –
28 68 M Prostate T1N1M1 –
29 71 M Prostate T1N1M1 –
30 73 M Prostate T1N1M1 –
31 74 M Prostate T1N1M1 –
32 71 M Prostate T2N1M1 –
33 68 M Prostate T1N1M1 –
34 65 M Prostate T1N1M1 –
35 69 M Prostate T1N1M0 –
36 71 M Prostate T1N1M1 –
37 70 M Prostate T1N1M1 –
38 83 M Colon-
rectum
T3N1M1 S
39 88 F Colon-
rectum
T4N1M1 –
40 84 M Colon-
rectum
T4N1M1 S
41 73 M Colon-
rectum
T3N1M1 S + CT
42 84 M Colon-
rectum
T3N1M1 S
43 84 M Colon-
rectum
T4N1M1 S
44 64 M Colon-
rectum
T4N1M1 –
45 63 M Lung T4N1M1 –
46 70 M Lung T4N1M0 CT
47 76 M Lung T4N1M0 –
48 85 M Lung T1N1M1 –
49 79 F Stomach T1N1M1 –






29 70.1 ± 17.7 19/10
CT, chemotheraphy; S, surgery.
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predictive value (NPV) with 95% conﬁdence interval were
calculated using standard formula.2.8. Statistical analysis
Results were expressed as means ± SD. Differences
among groups were assessed by one way analysis of vari-
ance (ANOVA) using SPSS for Windows version 16.0 (SPSS
Inc., Chicago, IL, USA).
3. Results
3.1. Standard curve from LNCaP
In each quantitative assay, a strong linear relation was demonstrated
between pg STEAP RNA and PCR cycles using LNCaP RNA for concentra-
tion (r2 > 0.99) and the efﬁciency of the reaction was always over 90%,
as assessed by the slope of standard curve for target gene (Fig. 1).
3.2. STEAP RNA quantiﬁcation
We obtained good quality of RNA from serum of patients and non-
malignant donors as evaluated by ratio of the absorbance at 260 and
280 nm (ranging from 1.8 to 2.0). In addition, by RT Real-Time PCR,
beta-2-microglobulin was positive in all samples (Ct < 30).
To quantify the STEAP RNA in serum of patients we performed the
Real-Time PCR by quantitative relative standard curve and we obtained
the ampliﬁcation corresponding to STEAP RNA in serum from patients
and non-malignant donors (Fig. 2).
The STEAP RNA in serum was positive in 92% of patients (Ct<40)
whereas two non-malignant donors presented low levels of STEAP RNA
ampliﬁable in serum (6.8%) (Ct > 40); on the contrary, in remaining non-
malignant donors, RNA was not ampliﬁable for STEAP.
3.3. Performance of the assay
Sensitivity, speciﬁcity positive predictive value and negative predic-
tive value of this molecular test were calculated from data presented in
Table 2. The calculated performance with 95% Conﬁdence Interval is
shown in Table 3.
There were no difference in age, histological type, clinical stage, and
presence of metastases among tumour patients. However, a negative cor-
relation between treatment and STEAP levels was observed even if it did
not reach the statistical signiﬁcance (Table 4).
4. Discussion
Biochemical analysis and secondary-structure predic-
tion suggest that STEAP is a cell-surface molecule with
six transmembrane domains; cell surface molecules with
six transmembrane domains are often ion channels [10]
that have been implicated in the proliferation and inva-
siveness of prostate cancer cells [3]. It is known that cells
expressing Na+ channels correlate positively with their
ability to invade basement membrane matrix in vitro. In
addition, in vitro studies suggest that the presence of Na+
channels in prostate carcinoma may act as a marker of
metastatic ability [4].
STEAP may affect intercellular communications also
indirectly by altering intracellular ion concentrations,
which in turn regulate gap or adherence junction activity
[11]. Nevertheless, cellular communications facilitate the
intercellular exchange of small molecular weight solutes,
such as nutrients, metabolites, electrolytes, and second
messengers from distant blood vessels, thus supporting tu-
mour growth. Many evidences from various models impli-
cate cell-communication in the ability of tumour cells to
invade and metastasize [12]. Structural domains of this
protein may suggest its involvement in tumour cell
Fig. 1. Standard curve for STEAP (Ct value = threshold cycle of RT PCR at which ﬂuorescence is detectable).
Fig. 2. STEAP mRNA ampliﬁcation in serum from cancer patients and non-malignant individuals by RT Real-Time PCR.
Table 2
STEAP expression in cancer patient and non-malignant individual serum
No. tumour patients Test results RNA STEAP (pg/ml)
46 Positive Median 5
Mean 7.39
Ranks range 2.4–25
4 Negative Not detectable
No. normal donors Test results RNA STEAP (pg/ml)
2 Positive Median –
Mean 1.65
Ranks range 1.5–1.8
27 Negative Not detectable
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called the apoptosis, cancer and redox associated trans-
membrane domain, which is present in a structurally re-
lated family identiﬁed recently to include members of
the STEAP family, as the bacterial Nox family and the YedZ
family of oxidoreductase [13].Table 3
Performance of STEAP RT Real-Time PCR in serum of tumour patients






STEAP levels in metastatic and non-metastatic and treated and untreated
patients
Patients RNA STEAP (pg/ml) p
Treatment
Treated 4.9 ± 4.5 ns
Untreated 7.6 ± 5.2
Metastases
Metastatic 6.7 ± 4.9 ns
Non-metastatic 7.4 ± 7.0
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prostate cancer but also in numerous human cancer cell
lines from pancreas, colon, breast, testicular, cervical, blad-
der and ovarian carcinoma, acute lymphocytic leukaemia
and Ewing sarcoma [2]. Moreover, the characteristics of
STEAP above described have validated it as a novel target
with the desirable characteristics for antibody therapy.
The clinical use ofmonoclonal antibody as cancer therapeu-
tics has been realized in the last few years with successful
commercialization of antibody products; the successful
generation of two monoclonal antibodies (mAb) that bind
to cell surface STEAP-1 epitopes provided the tools to study
STEAP-1 susceptibility to naked antibody therapy [12].
This is the ﬁrst time that STEAP-related RNA has been re-
ported in the serum of tumour patients. The presence of
STEAP RNA in the serum of tumour patients is probably
the reﬂexion of this RNA in the tumour cells; in addition,
a high percentage of sera from non-malignant donors re-
sulted negative and an important percentage of tumour pa-
tient sera were positive. The approach by RT Real-Time PCR
allowed also a quantiﬁcation of this marker in the serum of
patients.
We performed the analysis of possible inﬂuencing fac-
tors, including age, histological type, clinical stage of can-
cer and presence of the treatment. None of these factors
inﬂuenced signiﬁcantly the STEAP mRNA levels, even if
we observed lower values of STEAP mRNA in treated with
respect to untreated patients. However, in our study, the
high speciﬁcity and sensibility of the method indicates that
the STEAP mRNA in serum may be useful to discriminate
cancer patients from normal individuals.
On the basis of this ﬁnding, STEAP RNA should be uti-
lized as a useful cancer marker and, as previous studies
have shown that this protein is frequently expressed in dif-
ferent neoplastic diseases, the relative serum analysis may
be applied to the detection of a broad range of cancers.Even if these ﬁndings are intriguing, further and larger
studies are needed to conﬁrm the role of this marker in
detecting tumours as well as to verify the possibility to
use RNA STEAP as a non invasive follow-up marker for can-
cer patients.Conﬂict of interest statement
All the authors disclose any ﬁnancial and personal con-
ﬂict of interest.
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